Bruce serves as a board member to Sionna and is also a partner at Atlas Venture where he focuses on the discovery and development of novel medicines and therapeutic platforms. Currently, Bruce is chairman of Arkuda Therapeutics, AvroBio, Hotspot Therapeutics, Kymera Therapeutics, Nimbus Therapeutics, Quench Bio and Vigil Neuroscience. He also serves on the board of Magenta Therapeutics and several seed-stage companies. He previously served on the boards of past Atlas companies, including Avila (acquired by Celgene), Lysosomal Therapeutics, miRagen, Padlock (acquired by BMS), Prestwick (acquired by Biovail), Stromedix (acquired by Biogen), Rodin Therapeutics (acquired by Alkermes) and several other ventures. Bruce serves or has served as an advisor in various capacities to Takeda, UCB and the Gates Foundation. Before joining Atlas in 2005, Bruce was a consultant at McKinsey & Company, as well as an investor for Caxton Health Holdings. Bruce was a British Marshall Scholar and received a D.Phil. in molecular immunology from Oxford University. He received a B.S. in biochemistry, summa cum laude, from The Pennsylvania State University.